| Numbers | P-value | Hazard Ratio (95 % CI) | |
---|---|---|---|---|
Univariate | Multivariate | |||
Demographics | ||||
 Age (yrs), ≤65 vs. >65 | 100 vs. 56 | 0.613 |  |  |
 Gender, Female vs. Male | 29 vs. 127 | 0.863 |  |  |
 BMI (kgs/m2), ≤22 (24) vs. >22 (24) | 102 vs. 54 | 0.798 |  |  |
 Average dose (mg/kg), ≤35 vs. >35 | 97 vs. 59 | 0.848 |  |  |
 Cirrhosis, (-) vs. (+) | 36 vs. 120 | 0.263 |  |  |
 CPC, score 5 vs. 6 | 81 vs. 75 | 0.015* | 0.049* | 0.492 (0.213–1.137) |
 AE, (-) vs. (+) | 57 vs. 99 | <0.001* | 0.015* | 3.423 (1.274–9.199) |
Biochemical values | ||||
 Albumin (g/dL), ≤3.5 vs. >3.5 | 35 vs. 121 | 0.061 |  |  |
 Bilirubin (mg/dL), ≤1.3 vs. > 1.3 | 118 vs. 38 | 0.466 |  |  |
 INR, ≤1.2 vs. >1.2 | 116 vs. 40 | 0.321 |  |  |
 AST (IU/L), ≤34 vs. >34 | 25 vs. 130 | 0.181 |  |  |
 ALT (IU/L), ≤40 vs. >40 | 73 vs.83 | 0.036* |  |  |
 Alk-p (IU/L), ≤126 vs. >126 | 87 vs.39 | 0.051 |  |  |
 AFP (ng/mL), ≤9 vs. > 9 | 34 vs. 122 | <0.001* | 0.003* | 0.213 (0.078–0.583) |
 Creatinine (mg/dL), ≤1.3 vs. > 1.3 | 138 vs. 18 | 0.188 |  |  |
 WBC (103/dL), ≤105 vs. >105 | 136 vs.17 | 0.553 |  |  |
 Hb (gm/dL), ≤12 vs. >12 | 62 vs.94 | 0.115 |  |  |
 Platelet (103/uL), ≤130 vs. >130 | 61 vs. 95 | 0.207 |  |  |
Virologic values | ||||
 HBV or HCV, (-) vs. (+) | 21 vs. 135 | 0.873 |  |  |
 Tumor characters |  |  |  |  |
 Tumor size, ≤5 vs. >5 | 82 vs. 74 | 0.046* |  |  |
 Tumor numbers, ≤3 vs. >3 | 65 vs. 91 | 0.001* | 0.009* | 0.313 (0.131–0.747) |
 Intra-hepatic vein, (-) vs. (+) | 95 vs. 61 | 0.661 |  |  |
 Extra-hepatic metastases, (-) vs. (+) | 81 vs. 75 | 0.388 |  |  |
 Mixed type (vein and metastases), (-) vs. (+) | 136 vs. 20 | 0.517 |  |  |
Therapeutic response | ||||
 Sorafenib duration, cycle ≤ 1 vs. >1 | 75vs. 81 | <0.001* | 0.004* | 3.694 (1.530–8.920) |
 TACE (-) vs. (+) | 89 vs. 67 | 0.031* | 0.008* | 3.197 (1.353–7.553) |